Abstract

The C-type lectin family member lectin-like oxidized LDL receptor-1 (LOX-1) has been object of intensive research. Its modulation may offer a broad spectrum of therapeutic interventions ranging from cardiovascular diseases to cancer. LOX-1 mediates uptake of oxLDL by vascular cells and plays an important role in the initiation of endothelial dysfunction and its progression to atherosclerosis. So far only a few compounds targeting oxLDL-LOX-1 interaction are reported with a limited level of characterization. Here we describe the identification and characterization of BI-0115, a selective small molecule inhibitor of LOX-1 that blocks cellular uptake of oxLDL. Identified by a high throughput screening campaign, biophysical analysis shows that BI-0115 binding triggers receptor inhibition by formation of dimers of the homodimeric ligand binding domain. The structure of LOX-1 bound to BI-0115 shows that inter-ligand interactions at the receptor interfaces are key to the formation of the receptor tetramer thereby blocking oxLDL binding.

Highlights

  • The C-type lectin family member lectin-like oxidized LDL receptor-1 (LOX-1) has been object of intensive research

  • Besides the major risk factors such as high serum levels of total cholesterol or low-density lipoprotein cholesterol (LDLC), non-traditional risk factors are emerging as being important for predisposing to this disease, as many coronary artery disease (CAD) events are not prevented by only LDLC lowering therapy

  • To identify small molecule inhibitors of LOX-1 mediated oxidized low-density lipoproteins (oxLDL) uptake we developed a cellular high throughput screening (HTS) assay

Read more

Summary

Introduction

The C-type lectin family member lectin-like oxidized LDL receptor-1 (LOX-1) has been object of intensive research. We provide the crystallographic structure of a small molecule (BI-0115)-LOX-1 receptor complex, which shows atomic details of the protein-ligand interaction and the structural basis of the inhibitory mode-of-action. To identify small molecule inhibitors of LOX-1 mediated oxLDL uptake we developed a cellular high throughput screening (HTS) assay.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call